EU CHMP Opinions And MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU CHMP Opinions and MAA Updates
• Source: Pink Sheet/Shutterstock

The European Medicines Agency's key scientific panel, the Committee for Medicinal Products for Human Use (CHMP), meets once a month and among other things adopts positive or negative opinions on EU marketing authorization applications (MAAs) filed through the centralized procedure for new molecular entities (NMEs), biosimilars and generic medicines. CHMP opinions are sent to the European Commission, which makes a final, legally binding decision, usually within 67 days.

The CHMP at its monthly plenary meetings also assesses requests for modifications or extensions to existing marketing authorizations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from European Performance Tracker

  • EU Accelerated Assessment Tracker

    Decisions on sponsor requests for accelerated assessment of planned EU marketing authorization applications that will be reviewed by the European Medicines Agency’s human medicines committee (the CHMP) as well as information on whether MAAs granted accelerated assessment retain fast-track status as they make their way through the EU centralized procedure. Updated monthly.

  • EU Approvals

    Products containing new active substances that have been approved for marketing in the EU under the EU’s centralized authorization procedure. Updated monthly.

  • EU Filings

    New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

More from Regulatory Trackers